AskBio, a subsidiary of Bayer (BAYN GY), announces FDA acceptance of a IND application for AB-1009 gene therapy being developed for the treatment of late-onset Pompe disease

AskBio's announcement regarding the FDA's acceptance of its IND application for AB-1009 signals a positive step in Bayer's investment in innovative gene therapies.

Newsquawk StaffPublished On the live feed at 9 more headlines followed before this page went public
Newsquawk headlinesUTC

LVMH (MC FP) is reportedly looking to sell its watchmaking brand Zenith, citing large financial losses, via Swissinfo; sources suggest the "sale file is ready"

Daily US Equity Opening News - China will reportedly approve NVDA H200 chips this quarter; STZ rises after earnings, JEF falls

AskBio, a subsidiary of Bayer (BAYN GY), announces FDA acceptance of a IND application for AB-1009 gene therapy being developed for the treatment of late-onset Pompe disease

US Treasury Secretary Bessent urges more Fed rate cuts, according to CNBC citing a draft speech

RevelioLabs Total Nonfarm Payrolls (Dec.): 71k (prev. -9k)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could enhance Bayer's positioning in the biotechnology sector and may generate investor interest, especially if the product progresses successfully, potentially impacting share performance in the pharmaceuticals space.

Related headlines

The whole workspace, free to try.

Try it free